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abstract: Objectives: This study aimed to evaluate the cause of thrombosis in Behçet’s disease (BD) patients, since 
abnormalities in coagulation and fibrinolytic parameters have shown contradictory results. Methods: Haemostatic 
parameters were retrospectively evaluated in BD patients treated between January 2007 and January 2011 at Sultan 
Qaboos University Hospital, Oman. The blood samples of 35 Omani BD patients and 30 healthy controls were 
analysed for factor VIII:C levels, activated protein C resistance (APCR), von Willebrand factor (vWF) antigens 
(Ag), collagen binding and ristocetin co-factor activity (RiCoF), antithrombin (AT), protein C (chromogenic and 
clotting), protein S, homocysteine, tissue plasminogen activator, plasminogen activator inhibitor, plasminogen, 
alpha 2-antiplasmin, lupus anticoagulant and anticardiolipin and beta2-glycoprotein-1 antibodies. Results: The 
mean values of factor VIII:C, vWF Ag, AT and protein S were significantly higher in the patient group (P = 0.01, 
0.006, 0.04 and 0.01, respectively). There was no deficiency in protein C. Screening for APCR, anticardiolipin 
antibodies, anti-beta2-glycoprotein-1 antibodies and lupus anticoagulant was negative and there were no differences 
in homocysteine levels, nor were there differences between patients with and without thrombosis. Six patients had 
elevated factor VIII:C levels (>150 IU/dL, P <0.02) which normalised on repeat measurements after three months. 
Conclusion: The elevation of factors VIII:C, vWF Ag and AT most likely represent an acute phase phenomenon. 
In this study, thrombophilic factors did not seem to explain thrombotic tendency. Therefore, further mechanistic 
studies in a larger group of patients are needed to elucidate the basis for thrombosis in BD. We hypothesise that 
active BD causes vasculitic endothelial perturbation with dysfunction, leading to the observed increased propensity 
for thrombosis.
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امللخ�ص: الهدف: هدفت هذه الدرا�صة اإىل معرفة �صبب خثار الدم عند مر�صى بهجت، حيث اإن درا�صات �صابقة كانت قد اأظهرت نتائج مت�صاربة يف موؤ�رشات 
اأخذت  و يناير 2011.   2007 امُلْرِقئات ا�صتعاديا ملر�صى عمانيني م�صابني مبر�س بهجت بني يناير  الطرق: حللت موؤ�رشات  الِفرْبين.  التخرث واْنِحَلُل 
 )APCR( املن�صط C ومقاومة بروتني VIII :C عينات من دم 35 مري�صا وقورنت بعينات دم من 30 اأ�صخا�صا اأ�صحاء ومت قيا�س املوؤ�رشات الآتية: عامل
وم�صت�صد عامل فون فيلي برانرد )vWF( واحتاد الكولجني ون�صاط متيم عامل ري�صتو�صتني )RiCoF(  وم�صادات الرثمبني )AT( وبروتني C وبروتني 
S وهومو�صي�صتني و من�صطات  ومثبطات بلزمنوجني الأن�صجة والبلزموجنني و الفا 2 م�صاد البلزمني  وم�صادات تخرث الذئبة  وم�صادات كارديوليبني 
واأ�صداد بيتا 2 غليكو بروتينات 1. النتائج: وجد اأن هنالك ارتفاعا يف متو�صط املوؤ�رشات الآتية:، S protein ،AT ،vWFAg ،VIII:C يف املر�صى 
مقارنة بالأ�صحاء )and 0.04 ،0.006 ،0.01 = P 0.01، بالتتابع( مل يوجد اختلف يف بقية املتثبتات. مل يوجد  اأي�صا اختلف يف م�صتوى متثبتات 
 P  ،IU/dL  150<(  FVIII متثابتة  م�صتوى  قيا�س  عندهم    املر�صى  بني  من   6 كان  امل�صابني.  وغري  بالتجلطات  امل�صابني  املر�صى  بني  التخرث 
 ،AT ،vWFAg ،VIII:C ،اإىل امل�صتوى الطبيعي بعد 3 اأ�صهر بعد اإعادة قيا�صه. اخلال�صة: اإن ارتفاع موؤ�رشات التخرث FVIII 0.02(. رجعت متثابتة>
S protein رمبا كانت نتيجة لزيادة ن�صاط املر�س. مل تثبت هذه الدرا�صة اأن عوامل التخرث تف�رش ب�صكل مبا�رش قابلية التخرث يف هذا املر�س. يجب عمل 
مزيد من الدرا�صات لت�صمل عدد اأكرب من املر�صى ملعرفة �صبب قابلية التخرث يف هذا املر�س. نعتقد باأن التهاب جدار الأوعية  الدموية نتيجة مر�س بهجت 
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Advances in Knowledge
- The study showed that thrombophilia is unlikely to play a role in the thrombosis associated with Behçet’s disease.
Application to Patient Care
- Anti-inflammatory and immunosuppressive therapies, rather than prolonged anticoagulation treatment, seem to be an appropriate 
therapeutic approach to Behçet’s disease.
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Behçet’s disease (BD) is a multisystem vasculitic, chronic relapsing disorder of unknown aetiology associated with 
considerable morbidity and mainly occurring with eye 
involvement.1 It is also associated with an increase in 
mortality. Yazici et al. reported an overall mortality 
of 4% among a group of 152 Turkish patients after 10 
years of follow-up.2 However, a long-term outcome 
survey of Turkish patients showed an even higher 
mortality rate. Kural-Seyahi et al. surveyed the 20-
year outcome in a cohort of BD patients and found 
an overall mortality rate of 9.8%.3 The standardised 
mortality rate (SMR) was higher among males and, 
in particular, younger males (14–24 years), with a 
SMR reaching 10 times that observed in the general 
population. A significant proportion of this mortality 
(40%) was related to vascular thrombosis.3 In another 
study by Hamuryudan et al., a 50% mortality rate 
among 24 young male patients with pulmonary artery 
aneurysms was observed two years after the onset of 
the aneurysms.4
The vascular involvement in BD varies depending 
on the ethnic group.5 A Turkish study reported a 27% 
rate of vascular events,6 while a British study showed a 
prevalence of 32% with vascular thrombosis.7 A study 
from Saudi Arabia showed a prevalence of 43%.8
The pathogenesis of thrombotic events in BD is 
unknown. Although vasculitis is the predominant 
histopathological feature of the disease, it only 
partially explains the thrombotic phenomenon 
because endothelial-leukocyte interaction and plasma 
hypercoaguability both play an important role.9–19 
In fact, in other groups of vasculitic disorders, the 
frequency of major venous thrombosis is not as 
common as in BD. The extent of the thrombosis and 
its predilection for unusual sites suggests the presence 
of an underlying hypercoaguable state. It is believed 
that anticoagulant proteins and co-factors in plasma 
as well as the endothelium regulate the blood 
coagulation system. Under normal conditions, 
procoagulant and anticoagulant mechanisms are 
balanced and any disturbances result in thrombosis 
or bleeding. Abnormalities in coagulation and 
fibrinolytic systems have been reported in BD, but 
previous studies have shown contradictory results and 
as yet no single abnormality has been identified as the 
sole leading cause [Table 1].
In this study the coagulation and fibrinolytic factors 
were investigated in a group of Omani patients with 
BD and compared with the findings of other studies.
Methods
The subjects for this retrospective cross-sectional 
study fulfilled the criteria of the International 
Study Group for Diagnosis of Behçet’s Disease and 
were recruited from patients of the Rheumatology 
Outpatient Department at Sultan Qaboos University 
Hospital, Muscat, Oman, treated between January 
2007 and January 2011. Informed consent was 
obtained from the patients and approval was granted 
from the Medical Research & Ethics Committee of 
the College of Medicine & Health Sciences at Sultan 
Qaboos University (MRS/06/04).
Pregnant patients, those with malignancies or 
those receiving medications known to interfere with 
haemostasis were excluded, as were those patients 
unwilling to give informed consent. A total of 35 
consecutive patients were thus enrolled along with 
a control group of 30 subjects matched for age, race 
and sex. Various clinical data were recorded, including 
age at onset, disease duration, current disease activity 
and manifestations of the disease (current and past). 
These data included vascular involvement, the 
presence of associated cardiovascular disorders and 
treatment regimens. Patients were considered to have 
an active form of the disease if they had shown any 
of the following criteria within the previous month: 
oral, gastrointestinal or genital ulcers; eye or vascular 
lesions; arthritis, or central nervous system (CNS) 
involvement.
Venous blood samples were collected from all 
subjects between 9 and 10 am to minimise diurnal 
variation in the levels of biological, haemostatic 
and rheological factors. Blood was collected from 
the antecubital vein and anticoagulated with K2 
ethylene-diamine-tetra-acetic acid (EDTA) and 
trisodium citrate (0.11 M: 9:1 v:v). Citrated plasma 
was double-centrifuged the same day within 
two hours of collection and stored at -70 °C for 
further studies. Plasma activities of coagulation 
inhibitors (antithrombins [AT]; proteins C and S; 
von Willebrand factor (vWF) antigens (Ag); factor 
VIII:C; tissue plasminogen activators (t-PA) antigens 
and activity; plasminogen activator inhibitors (PAI-
1); plasminogen; alpha 2-antiplasmin, and activated 
protein C resistance [APCR]) were determined using 
standard techniques as per the manufacturers’ advice. 
The reagents were obtained from Diagnostica Stago, 
Inc. (Asnières-sur-Seine, France) and Instrumentation 
Laboratory (Barcelona, Spain). The reference ranges 
used were as follows: functional protein S - 77–143 IU/
dL for males and 55–123 IU/dL for females; functional 
chromogenic protein C - 65–110 IU/dL; functional 
protein C (clotting assay) - 66–131 IU/dL; functional 
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AT - 67–109 IU/dL; factor VIII:C levels - 50–150 
IU/dL; vWF Ag - 50–158 IU/dL; vWF:ristocetin co-
factor activity (RiCoF) - 40–150 IU/dL; vWF:collagen 
binding activity (CBA) - 50–400 IU/dL; plasminogen 
- 73–127 IU/dL; alpha 2-antiplasmin - 89–112 IU/dL; 
t-plasminogen activator - 1–12 ng/mL; plasminogen 
activator inhibitors (PAI-1) - 4–43 ng/mL plasma, and 
homocysteine - 5–15 µmol/L. For APCR, if the sample 
showed an APC ratio of <2.1, then factor V Leiden was 
considered positive.
Statistical analysis was performed using the 
Statistical Package for the Social Sciences, Version 
10.0 (IBM, Corp. Chicago, Illinois, USA). Data were 
expressed as mean ± standard deviation (SD). For all 
Table 1: Results of selected previous studies
Author 
and year of 
study
N/n* Parameters studied Main findings Conclusion
Hampton 
et al.9
18/7 Fibrinogen, vWF, TPA, PAI-1, 
protein C, protein S, AT, factor VIII, 
fibrinogen peptides A, plasminogen 
and alpha 2-antiplasmin.
-Increased fibrinogen, vWF, 
TPA, PAI-1 and plasminogen 
activator.
-Decreased protein C.
-No difference between T+ 
and T-.
No abnormality 




30/16 Protein C, protein S and AT. Decreased free protein S and 
protein S activity.
Protein S deficiency 




25/8 ACA, LA, protein C, protein S, AT 
and APCR.
Elevated ACA and IgG but no 
relation to thrombosis.




96/22 Protein C, protein S, AT and 
fibrinogen.
-Increased AT.





127/34 Protein C, protein S, AT, fibrinogen, 
vWF, TM, prothrombin fragment F 
1+2 and TPA.








30/5 TFPI, ACA, fibrinogen, PAI-1, 
TPA, vWF, protein C, protein S, 
plasminogen and lipids.
-Increased TFPI and fibrinogen.
-Increased PAI-1 and APL-
positive in one subject.




39/7 Factor VII, GFC, protein C, protein 
S, AT, fibrinogen, lipids, APCR, 
APTT, PT, TT and ACA.
-Increased factor VII, 
decreased protein S in one 
patient, decreased protein C in 
one subject and APCR in one 
subject.
-No differences between T+ 
and T-.
Coagulation is activated 




24/7 Fibrinogen, vWF, factor VIII, factor 
XI, protein C, protein S, AT, LA and 
APCR.







39/12 Protein C, protein S, AT, APCR, 
factor VIII, vWF, TM, alpha 
1-antitrypsin and fibrinogen.
-Increased protein S, AT, alpha 
1-antitrypsin, factor VIII and 
vWF.
-Decreased APCR and TM 
(also decreased in T+).
Reduced APCR levels.
Lee et al.18 32/4
24/12
Fibrinogen, AT, protein C, protein 
S, vWF, ACA, LA, APCR and 
homocysteine.
-Increased fibrinogen, vWF and 
homocysteine.
-Decreased AT.
-aPL positive in one subject and 
LA positive in four subjects.
-No evidence of 
activation of coagulation
-Hypercysteinaemia may 
be a risk factor.
Leiba et al.19 107/33 Factor V, factor VIII, prothrombin 
G 20210A, MTHFR C 677T, plasma 
glucosylceramide, homocysteine and 
lipids.
-Increased factor VIII in T+.
-Increased lipids.
-No role for 
thrombophilia.
-Dyslipidaemia may be a 
risk factor.
n* = number of patients with thrombosis; vWf = von Willebrand factor; TPA = tissue plasminogen activator; PAI-1 = plasminogen activator inhibitor; 
AT = antithrombin; T+/T- = patients with/without thrombosis; BD = Behçet's disease; ACA = anticardiolipin antibodies; LA = lupus anticogulant; 
APCR = activated protein C resistance; IgG = immunoglobulin G; TM = thrombomodulin; TFPI = tissue factor pathway inhibitor; 
aPL = antiphospholipid antibodies; GFC = global fibrinolytic capacity; APTT = activated partial thromboplastin time; PT = prothrombin time; 
TT = thrombin time; G 20210 A = prothrombin mutation G20210A; MTHFR = methylenetetrahydrofolate reductase.
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tests, values of P <0.05 (two-tailed) were considered 
statistically significant. Fisher’s exact test, the Mann-
Whitney (MW) test and Spearman’s correlation test 
were used.
Results
The male to female ratio was approximately 2:1.
The mean age ± SD of the patients and controls 
were 32 ± 8 and 32 ± 7 years, respectively. The 
mean ± SD disease duration was 10 ± 6.5 years. The 
demographic details of all subject and the clinical 
manifestations of the patients are summarised in 
Tables 2 and 3. Eight patients with BD had thrombotic 
events. Of those patients, four had current vascular 
events: one had deep vein thrombosis (DVT); two had 
pulmonary artery aneurysms; one had a concomitant 
stroke, and one a stroke. The other four BD patients 
had a previous history of thrombosis (stroke  = 1; 
DVT = 2; pulmonary artery aneurysms =1). The mean 
age of patients with thrombosis was 24 years (range 
15–37 years). The mean time-lag between blood tests 
and vascular events in patients with a past history of 
thrombosis was seven years (range 2–15 years).
The blood samples showed significantly elevated 
factor VIII:C, vWF Ag, AT and protein S function in 
BD patients compared with the controls [Figure 1]. Six 
patients with a raised factor VIII of >150 IU/dL had an 
active form of the disease. One of these patients had a 
vascular event at the time of measurement. There were 
no deficiencies in protein C or APCR. Furthermore, 
no differences in anticardiolipin antibodies, anti-
beta2-glycoprotein-1 antibodies, lupus anticoagulant, 
TPA, PAI-1, plasminogen, alpha 2-antiplasmin, 
homocysteine, total cholesterol, triglycerides or blood 
glucose levels were found in BD patients compared 
to the controls. There were no differences in the 
thrombophilic or fibrinolytic factors studied between 
patients with and without thrombosis. Elevated factor 
VIII levels normalised on repeating the measurements 
after three months and once the disease became 
inactive. Figure 1 and Table 4 summarise the 
haemostatic results.
There was no difference between erythrocyte 
sedimentation rates or C-reactive protein levels 
between patients and controls. However, the 20 
patients with clinically active forms of the disease 
had raised levels of factor VIII:C (P = 0.01); vWF Ag 
(P = 0.02); vWF:RiCoF (P = 0.04), and vWF:CBA (P = 
0.01), as compared to the 15 patients with the inactive 
form of the disease. Positive correlations were found 
between factor VIII:C and vWF Ag levels (r = 0.63, P = 
0.001);  factor VIII:C and vWF:RiCoF levels (r = 0.64, 
P = 0.001); factor VIII:C, and vWF:CBA levels (r = 0.7, 
P = 0.001) after performing the different blood tests in 
the patient group.
Discussion
The vascular complications of BD represent a 
challenging aspect of the disease in terms of 
determining the aetiopathogenesis and, more 
importantly, considering management options. 
Moreover, there is still no clear or adequate explanation 
for the thrombotic tendency.
Table 2: Demographic details and clinical manifestations of study patients and controls with Behçet’s 
disease









Age in years, mean ± SD 32 ± 8 32 ± 7 0.65 31 ± 8 32 ± 7 0.70
Gender by male:female ratio 23:12 18:12 - -  - -
Disease duration in years, mean 
± SD
10 ± 6.5 - - 10 ± 7 9 ± 6 0.40
Clinically active disease 20 - - 5 15 0.90
T+ = patients with thrombosis; T- = patients without thrombosis; SD = standard deviation.
Table 3: Clinical manifestations of study patients 
with Behçet’s disease









GI = gastrointestinal: CNS = central nervous sustem.
*Abdominal pain, constipation or ulcer; **Headache, numbness, 
paresis and without imaging evidence of thrombosis.
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High levels of factor VIII were associated with an 
increased risk of vascular thrombosis in the Leiden 
Thrombophilia Study.20 Individuals with factor VIII 
activity levels ≥150 IU/dL are associated with a 
five- to six-fold increased risk of venous thrombosis 
compared to levels <100 IU/dL. Significantly higher 
levels of factor VIII were found in BD patients 
compared to controls as has also been reported 
by other investigators as well as in some case series 
associated with thrombosis;16,17,19,21,22 however, other 
studies have shown normal results.9 Nonetheless, 
in contrast to other studies, follow-up studies found 
that the level of factor VIII normalised on repeated 
measurements which suggests that this elevation was 
merely due to an acute phase reaction.23 This might 
explain the lack of association of thrombosis and 
raised factor VIII levels in the patients of the current 
study, as well as other studies. This is because the 
level of factor VIII concentration varies with disease 
activity; an acute phase reactant may not necessarily 
predict a thrombotic risk unless follow-up studies 
show persistently elevated levels. In support of this, 
the current study clearly shows that all patients with 
raised factor VIII levels had an active form of the 
disease and that once their disease status/activity was 
under control, the factor VIII levels returned to within 
normal laboratory reference ranges. Furthermore, 
studies which investigated factor VIII level as a risk 
factor for venous thrombosis in the general population 
with idiopathic DVT found that high levels of factor 
VIII usually persisted over time—up to five years in 
some cases—and were independent of acute phase 
proteins.23 Thus, the reported differences in factor VIII 
levels could be partially explained by the inherently 
different disease activity statuses in different series in 
the reported literature.
As an endothelial cell product, which mediates 
platelet aggregation and adhesion to the injured 
endothelium, vWF helps in platelet plug formation. The 
other important function of vWF is that it enhances the 
coagulation system by stabilising as well as protecting 
factor VIII from its proteolytic inactivation.23,24 In BD, 
elevated levels of vWF have been recorded, as is the 
case in several other atherosclerotic diseases. In fact, 
Table 4: Haemostatic parameters in Behçet’s disease 
patients with and without thrombosis (n = 35)





Factor VIII:C in IU/dL 120 ± 30 102 ± 52 0.10
Protein C [Ch] in IU/dL 199 ± 21 127 ± 41 0.90
Protein C [clot] in IU/dL 124 ± 28 143 ± 46 0.48
Protein S [func] in IU/dL 103 ± 19 100 ± 30 0.60
Antithrombin in IU/dL 111 ± 12 107 ± 12 0.45
Plasminogen in IU/dL 118 ± 14 113 ± 16 0.40
Alpha 2-antiplasmin in 
IU/dL
118 ± 12 119 ± 16 0.90
APCR ratio* >2.1 >2.1 -
TPA in ng/mL 8 ± 5 7 ± 3 0.98
PAI-1 in ng/mL 26 ± 14 33 ± 22 0.70
vWF Ag in IU/dL 99 ± 14 102 ± 38 0.76
vWF:RiCoF in IU/dL 106 ± 19 99 ± 50 0.22
vWF:CBA in IU/dL 105 ± 27 99 ± 50 0.36
T+ = patients with thrombosis; T- = patients without thrombosis; 
[Ch] = chromogenic; [func] = functional; APCR = activated protein C 
resistance; TPA = tissue plasminogen activator; PAI-1 = plasminogen 
activator inhibitor; vWF Ag = von Willebrand factor antigen; RiCoF = 
ristocetin co-factor activity; CBA = collagen binding activity.
*If activated protein C ratio was <2.1 then factor V Leiden was 
considered positive.
Figure 1: Haemostatic parameters in Behçet’s disease patients and controls.
BD = Behçet’s disease; [Ch] = chromogenic; [func] = functional; APC = activated protein C; TPA = tissue plasminogen activator; PAI-1 = 
plasminogen activator inhibitor; vWF-Ag = von Willebrand factor antigen; RiCoF = ristocetin co-factor activity; CBA = collagen binding activity.
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some studies have suggested that high plasma levels 
of vWF in subjects with cerebrovascular disease 
(CVD) can predict the subsequent occurrence of 
major clinical events such as death and myocardial 
infarction.24 Furthermore, levels of vWF are elevated 
in other comorbid conditions which predispose 
individuals to atherosclerosis, such as hypertension 
and diabetes. The precise mechanism for the increase 
in vWF in CVD remains uncertain and there is debate 
as to whether the high levels of vWF seen in CVD 
disorders are the cause or consequence of the disease 
process.24 High levels may merely reflect the extent 
of vascular damage or may reflect platelet activation 
which is a consistent companion of endothelial 
damage. In most studies in the literature, as was found 
in the patients of the current study, raised vWF levels 
in cases of BD was an almost constant finding. This 
could be the consequence of a chronic perturbation 
and stimulation of the vascular endothelium.
The current study is in agreement with many other 
studies in that the results showed no deficiencies in 
the natural anticoagulants levels of AT, protein S or 
protein C. On the contrary, the levels of both AT and 
protein S were elevated. Sengül et al.12 and Probst 
et al.16 found elevated levels similar to those in the 
current study. These authors explained this elevation 
as a result of a compensatory mechanism against 
the increased procoagulant activity. However, these 
differences could be multifactorial and may result 
from the different disease activity statuses in different 
series and/or may reflect a response to the endothelial 
damage. Thus, a combination of vasculitis, endothelial-
leucocyte interaction with altered function, alterations 
in procoagulant and anticoagulant levels and altered 
cytokines will result in the variability of the disease 
activity and severity.
No significant differences in the plasma 
homocystine levels between BD patients and controls 
were found in this study, although two patients had 
significantly elevated plasma levels. However, there is 
increasing evidence to suggest that the vascular effects 
of elevated plasma homocysteine are mediated through 
an action on the endothelium by lipid peroxidation, 
altered vascular tone and a hypercoaguable 
prorombotic state leading to atherothrombogenesis.25
Conclusion
Although this study is limited by the small number 
of patients and its retrospective design, the findings 
show that underlying thrombophilia is unlikely to play 
a significant role in the pathogenesis of thrombosis 
in BD patients. Like many other studies, no distinct 
abnormalities were found either in the coagulants, 
anticoagulants or in the fibrinolytic system. Endothelial 
dysfunction as a consequence of the vasculitic process 
seems to be the most probable initial event. This has 
implications for the management of vascular BD as 
anti-inflammatory and immunosuppressive therapy, 
rather than prolonged anticoagulation treatment, 
seems to be the most appropriate therapeutic approach 
to treatment. In fact, the latest European League 
Against Rheumatism guidelines for the management 
of BD state that “There are no controlled data on, or 
evidence of benefit from, uncontrolled experience 
with anticoagulants, anti-platelet or fibrinolytic agents 
in the management of deep vein thrombosis, or for the 
use of anticoagulation for the arterial lesions of BD”.26 
The recommendation is to use immunosuppressive 
agents to manage the vascular aspect of BD.
A prospective study in a sufficiently large 
number of patients would be able to test this 
management strategy by randomising patient treatment 
with anti-inflammatory/immunosuppressive versus 
anticoagulation therapy. This would require a 
multicentre, multinational approach. It is the authors’ 
endeavour to initiate a multicentre registry so that the 
above strategy can be implemented.
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